Vimarsana
Biggest News Aggregation in the World

Renal Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Renal Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Renal Cell Today - Breaking & Trending Today

Future Perspectives and Unmet Needs in Renal Cell Carcinoma - Vimarsana News

Future Perspectives and Unmet Needs in Renal Cell Carcinoma

The expert panel provides key takeaways and closing thoughts on future perspectives and unmet needs in the treatment of renal cell carcinoma.

Case Study: Experienced Urologist Needed For ANDA IP Infringement Dispute - Life Sciences, Biotechnology & Nanotechnology - Vimarsana News

Case Study: Experienced Urologist Needed For ANDA IP Infringement Dispute - Life Sciences, Biotechnology & Nanotechnology

The defendant approached WIT to provide an expert who could help bring their drug to market and invalidate the claims of the plaintiff.

Source: mondaq.com
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers - Vimarsana News

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo to be shared in a late-breaking oral presentation Four-year data from CheckMate -9ER and...

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma - Vimarsana News

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ...

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 - Vimarsana News

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in...